These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36717650)

  • 1. Assessment of therapeutic role of mesenchymal stromal cells in mouse models of graft-versus-host disease using cryo-imaging.
    Wuttisarnwattana P; Eid S; Wilson DL; Cooke KR
    Sci Rep; 2023 Jan; 13(1):1698. PubMed ID: 36717650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryo-imaging of Stem Cell Biodistribution in Mouse Model of Graft-Versus-Host-Disease.
    Wuttisarnwattana P; Eid S; Gargesha M; Cooke KR; Wilson DL
    Ann Biomed Eng; 2020 Jun; 48(6):1702-1711. PubMed ID: 32103369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of Graft-versus-Host-Disease in NOD.Cg-Prkdc
    Hansen M; Stahl L; Heider A; Hilger N; Sack U; Kirschner A; Cross M; Fricke S
    Transplant Cell Ther; 2021 Aug; 27(8):658.e1-658.e10. PubMed ID: 33964513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
    Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
    Front Immunol; 2019; 10():619. PubMed ID: 31001253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice.
    Jang MJ; Kim HS; Lee HG; Kim GJ; Jeon HG; Shin HS; Chang SK; Hur GH; Chong SY; Oh D; Chung HM
    Acta Haematol; 2013; 129(4):197-206. PubMed ID: 23257958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
    Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
    Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of bone marrow mesenchymal stem cells on hematopoietic recovery and acute graft-versus-host disease in murine allogeneic umbilical cord blood transplantation model.
    Li ZY; Wang CQ; Lu G; Pan XY; Xu KL
    Cell Biochem Biophys; 2014 Sep; 70(1):115-22. PubMed ID: 24696072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experiment study of efficacy on hematopoietic reconstitution and GVHD prophylaxis after mesenchymal cell infused by intra-bone marrow cavity or intravenous in rat BMT models].
    Huang K; Huang SL; Zhou DH; Cai Y; Zhang XC; Li Y
    Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):87-92. PubMed ID: 17650667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease.
    Fan X; Guo D; Cheung AMS; Poon ZY; Yap CS; Goh SE; Guo D; Li H; Bari S; Li S; Lim KH; Hwang WYK
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):1971-1980. PubMed ID: 29883796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation.
    Silva IA; Olkiewicz K; Askew D; Fisher JM; Chaudhary MN; Vannella KM; Deurloo DT; Choi SW; Pierce EM; Clouthier SG; Liu C; Cooke KR
    Biol Blood Marrow Transplant; 2010 May; 16(5):598-611. PubMed ID: 20117226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.
    Auletta JJ; Eid SK; Wuttisarnwattana P; Silva I; Metheny L; Keller MD; Guardia-Wolff R; Liu C; Wang F; Bowen T; Lee Z; Solchaga LA; Ganguly S; Tyler M; Wilson DL; Cooke KR
    Stem Cells; 2015 Feb; 33(2):601-14. PubMed ID: 25336340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease.
    Kim KW; Moon SJ; Park MJ; Kim BM; Kim EK; Lee SH; Lee EJ; Chung BH; Yang CW; Cho ML
    Stem Cell Res Ther; 2015 Oct; 6():202. PubMed ID: 26497134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: a novel approach to separate GvHD from GvL effect.
    Li H; Jiang Y; Jiang X; Guo X; Ning H; Li Y; Liao L; Yao H; Wang X; Liu Y; Zhang Y; Chen H; Mao N
    Stem Cells; 2014 Jul; 32(7):1890-903. PubMed ID: 24496849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management.
    Mirfakhraie R; Ardakani MT; Hajifathali A; Karami S; Moshari MR; Hassani M; Firouz SM; Roshandel E
    Transpl Immunol; 2022 Apr; 71():101524. PubMed ID: 34990789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotypic characteristics of multipotent mesenchymal stromal cells that affect the efficacy of their use in the prevention of acute graft
    Petinati N; Kapranov N; Davydova Y; Bigildeev A; Pshenichnikova O; Karpenko D; Drize N; Kuzmina L; Parovichnikova E; Savchenko V
    World J Stem Cells; 2020 Nov; 12(11):1377-1395. PubMed ID: 33312405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model.
    Kuo YR; Goto S; Shih HS; Wang FS; Lin CC; Wang CT; Huang EY; Chen CL; Wei FC; Zheng XX; Lee WP
    Transplantation; 2009 Jun; 87(12):1769-77. PubMed ID: 19543052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.